ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

Group 1 - The article discusses the investment opportunities in ImmunityBio, Inc. (NASDAQ: IBRX), highlighting previous coverage and ratings issued by the author, including a "Hold" rating since April last year [1] - The Haggerston BioHealth marketplace channel offers exclusive stock tips focused on Pharma, Biotech, and Healthcare, providing access to financial models and research [1] - The investing group is designed for both novice and experienced biotech investors, offering insights on catalysts, product sales forecasts, and integrated financial statements [1] Group 2 - The author, Edmund Ingham, has over 5 years of experience in covering biotech, healthcare, and pharma, with detailed reports on over 1,000 companies [1]